| 14.05 17:50 | dpa-AFX: GNW-Adhoc: Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call |
| 14.05 17:50 | GNW-Adhoc: Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call |
| 14.05 17:45 | GlobeNewswire/Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call |
| 14.05 17:45 | Press Release: Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call |
| 14.05 17:45 | dpa-AFX: GNW-Adhoc: Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call |
| 06.05 18:40 | dpa-AFX: GNW-Adhoc: Bondholders approve amended terms of the 2024 convertible bonds |
| 06.05 18:40 | GNW-Adhoc: Bondholders approve amended terms of the 2024 convertible bonds |
| 06.05 18:35 | GlobeNewswire/Bondholders approve amended terms of the 2024 convertible bonds |
| 06.05 18:35 | Press Release: Bondholders approve amended terms of the 2024 convertible bonds |
| 06.05 18:35 | dpa-AFX: GNW-Adhoc: Bondholders approve amended terms of the 2024 convertible bonds |
| 01.05 18:05 | dpa-AFX: GNW-Adhoc: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond |
| 01.05 18:05 | GNW-Adhoc: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond |
| 01.05 18:00 | Press Release: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond |
| 01.05 18:00 | GlobeNewswire/Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond |
| 01.05 18:00 | dpa-AFX: GNW-Adhoc: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond |
| 26.04 07:05 | dpa-AFX: GNW-Adhoc: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension |
| 26.04 07:05 | GNW-Adhoc: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension |
| 26.04 07:00 | Press Release: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension |
| 26.04 07:00 | Press Release: JERAYGO (aprocitentan) recommended -2- |
| 26.04 07:00 | GlobeNewswire/JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension |
|
|
